Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Clinical success of the proteasome inhibitor established bortezomib as one of the most effective drugs in treatment of multiple myeloma (MM). While survival benefit of bortezomib generated new treatment strategies, the primary and secondary resistance of MM cells to bortezomib remains a clinical con...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Li, Chen, Jing, Han, Xiaoyan, Zhang, Enfan, Huang, Xi, Guo, Xing, Chen, Qingxiao, Wu, Wenjun, Zheng, Gaofeng, He, Donghua, Zhao, Yi, Yang, Yang, He, Jingsong, Cai, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Higher Education Press 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107487/
https://www.ncbi.nlm.nih.gov/pubmed/29441489
http://dx.doi.org/10.1007/s13238-017-0500-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107487/
https://www.ncbi.nlm.nih.gov/pubmed/29441489
http://dx.doi.org/10.1007/s13238-017-0500-9

Ejemplares similares